HOXD-AS1 is a novel lncRNA encoded in HOXD cluster and a marker of neuroblastoma progression revealed via integrative analysis of noncoding transcriptome

BMC Genomics

Volumn 15, Issue , 2014, Pages

  Yarmishyn, Aliaksandr A ^a   Batagov, Arsen O ^a   Tan, Jovina Z ^a   Sundaram, Gopinath M ^b   Sampath, Prabha ^b,c,d   Kuznetsov, Vladimir A ^a,e   Kurochkin, Igor V ^a  

^a BIOINFORMATICS INSTITUTE   (Singapore)

^b INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

^e NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

LONG NONCODING RNA 1; LONG NONCODING RNA 2; LONG NONCODING RNA 3; LONG UNTRANSLATED RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RETINOIC ACID; TRANSCRIPTOME; TUMOR MARKER; UNCLASSIFIED DRUG; MESSENGER RNA; TRANSCRIPTION FACTOR;

ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CELL DIFFERENTIATION; CELL NUCLEUS; COHORT ANALYSIS; CONTROLLED STUDY; CYTOPLASM; GENE EXPRESSION REGULATION; GENE LOCATION; GENE ONTOLOGY; GENE SILENCING; GENETIC ASSOCIATION; HOXD AS1 GENE; HOXD1 GENE; HOXD2 GENE; HUMAN; HUMAN CELL; METASTASIS; MICROARRAY ANALYSIS; NEUROBLASTOMA; PRIMARY TUMOR; SIGNAL TRANSDUCTION; TUMOR GENE; UPREGULATION; DISEASE COURSE; GENE EXPRESSION PROFILING; GENE LOCUS; GENETICS; METABOLISM; MOLECULAR GENETICS; MULTIGENE FAMILY; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

HOMINIDAE;

BIOMARKERS, TUMOR; CELL LINE, TUMOR; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; GENETIC LOCI; HUMANS; MOLECULAR SEQUENCE ANNOTATION; MULTIGENE FAMILY; NEUROBLASTOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, LONG NONCODING; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84927156689     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-15-S9-S7     Document Type: Article

References (61)

1. Palanichamy JK, Rao DS: miRNA dysregulation in cancer: towards a mechanistic understanding. Front Genet 2014, 5:54.
2. Qiu MT, Hu JW, Yin R, Xu L: Long noncoding RNA: an emerging paradigm of cancer research. Tumour Biol 2013, 34:613-620.
3. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, Brzoska P, Kong B, Li R, West RB, van de Vijver MJ, Sukumar S, Chang HY: Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010, 464:1071-1076.
4. Ji P, Diederichs S, Wang W, Böing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, Thomas M, Berdel WE, Serve H, Müller-Tidow C:MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003, 22:8031-8041.
5. Tano K, Mizuno R, Okada T, Rakwal R, Shibato J, Masuo Y, Ijiri K, Akimitsu N:MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes. FEBS Lett 2010, 584:4575-4580.
6. Janoueix-Lerosey I, Schleiermacher G, Delattre O: Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene 2010, 29:1566-1579.
7. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993, 11:1466-1477.
8. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984, 224:1121-1124.
9. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985, 313:1111-1116.
10. Berwanger B, Hartmann O, Bergmann E, Bernard S, Nielsen D, Krause M, Kartal A, Flynn D, Wiedemeyer R, Schwab M, Schäfer H, Christiansen H, Eilers M: Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. Cancer Cell 2002, 2:377-386.
11. Ohira M, Oba S, Nakamura Y, Isogai E, Kaneko S, Nakagawa A, Hirata T, Kubo H, Goto T, Yamada S, Yoshida Y, Fuchioka M, Ishii S, Nakagawara A:Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 2005, 7:337-350.
12. Schramm A, Schulte JH, Klein-Hitpass L, Havers W, Sieverts H, Berwanger B, Christiansen H, Warnat P, Brors B, Eils J, Eils R, Eggert A: Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene 2005, 24:7902-7912.
13. Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H, Matthay K, Buckley J, Ortega A, Seeger RC: Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst 2006, 98:1193-1203.
14. Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, Ernestus K, König R, Haas S, Eils R, Schwab M, Brors B, Westermann F, Fischer M:Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006, 24:5070-5078.
15. Krasnoselsky AL, Whiteford CC, Wei JS, Bilke S, Westermann F, Chen QR, Khan J: Altered expression of cell cycle genes distinguishes aggressive neuroblastoma. Oncogene 2005, 24:1533-1541.
16. Fredlund E, Ringnér M, Maris JM, Påhlman S: High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci USA 2008, 105:14094-14099.
17. Liu X, Mazanek P, Dam V, Wang Q, Zhao H, Guo R, Jagannathan J, Cnaan A, Maris JM, Hogarty MD: Deregulated Wnt/beta-catenin program in highrisk neuroblastomas without MYCN amplification. Oncogene 2008, 27:1478-1488.
18. Westermann F, Muth D, Benner A, Bauer T, Henrich KO, Oberthuer A, Brors B, Beissbarth T, Vandesompele J, Pattyn F, Hero B, König R, Fischer M, Schwab M:Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol 2008, 9:R150.
19. Bourdeaut F, Janoueix-Lerosey I, Lucchesi C, Paris R, Ribeiro A, de Pontual L, Amiel J, Lyonnet S, Pierron G, Michon J, Peuchmaur M, Delattre O:Cholinergic switch associated with morphological differentiation in neuroblastoma. J Pathol 2009, 219:463-472.
20. Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ: Retinoid therapy of high-risk neuroblastoma. Cancer Lett 2003, 197:185-192.
21. Thiele CJ, Deutsch LA, Israel MA: The expression of multiple protooncogenes is differentially regulated during retinoic acid induced maturation of human neuroblastoma cell lines. Oncogene 1988, 3:281-288.
22. Bates SE, Mickley LA, Chen YN, Richert N, Rudick J, Biedler JL, Fojo AT:Expression of a drug resistance gene in human neuroblastoma cell lines:modulation by retinoic acid-induced differentiation. Mol Cell Biol 1989, 9:4337-4344.
23. Bown N, Cotterill S, Lastowska M, O'Neill S, Pearson AD, Plantaz D, Meddeb M, Danglot G, Brinkschmidt C, Christiansen H, Laureys G, Speleman F, Nicholson J, Bernheim A, Betts DR, Vandesompele J, Van Roy N: Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999, 340:1954-1961.
24. Yu M, Ohira M, Li Y, Niizuma H, Oo ML, Zhu Y, Ozaki T, Isogai E, Nakamura Y, Koda T, Oba S, Yu B, Nakagawara A: High expression of ncRAN, a novel non-coding RNA mapped to chromosome 17q25.1, is associated with poor prognosis in neuroblastoma. Int J Oncol 2009, 34:931-938.
25. Zhu Y, Yu M, Li Z, Kong C, Bi J, Li J, Gao Z, Li Z:ncRAN, a newly identified long noncoding RNA, enhances human bladder tumor growth, invasion, and survival. Urology 2011, 77:510.e1-e5.
26. Calin GA, Liu CG, Ferracin M, Hyslop T, Spizzo R, Sevignani C, Fabbri M, Cimmino A, Lee EJ, Wojcik SE, Shimizu M, Tili E, Rossi S, Taccioli C, Pichiorri F, Liu X, Zupo S, Herlea V, Gramantieri L, Lanza G, Alder H, Rassenti L, Volinia S, Schmittgen TD, Kipps TJ, Negrini M, Croce CM:Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell 2007, 12:215-229.
27. Mestdagh P, Fredlund E, Pattyn F, Rihani A, Van Maerken T, Vermeulen J, Kumps C, Menten B, De Preter K, Schramm A, Schulte J, Noguera R, Schleiermacher G, Janoueix-Lerosey I, Laureys G, Powel R, Nittner D, Marine JC, Ringnér M, Speleman F, Vandesompele J: An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours. Oncogene 2010, 29:3583-3592.
28. Scaruffi P, Stigliani S, Moretti S, Coco S, De Vecchi C, Valdora F, Garaventa A, Bonassi S, Tonini GP: Transcribed-Ultra Conserved Region expression is associated with outcome in high-risk neuroblastoma. BMC Cancer 2009, 9:441.
29. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
30. Orlov YL, Zhou J, Lipovich L, Shahab A, Kuznetsov VA: Quality assessment of the Affymetrix U133A&B probesets by target sequence mapping and expression data analysis. In Silico Biol 2007, 7:241-260.
31. Badger JH, Olsen GJ: CRITICA: coding region identification tool invoking comparative analysis. Mol Biol Evol 1999, 16:512-524.
32. Frith MC, Bailey TL, Kasukawa T, Mignone F, Kummerfeld SK, Madera M, Sunkara S, Furuno M, Bult CJ, Quackenbush J, Kai C, Kawai J, Carninci P, Hayashizaki Y, Pesole G, Mattick JS: Discrimination of non-protein-coding transcripts from protein-coding mRNA. RNA Biol 2006, 3:40-48.
33. Kuznetsov VA, Knott GD, Bonner RF: General statistics of stochastic process of gene expression in eukaryotic cells. Genetics 2002, 161:1321-1332.
34. Chua ALS, Ivshina AV, Kuznetsov VA: Pareto-gamma statistic reveals global rescaling in transcriptomes of low and high aggressive breast cancer phenotypes. Lecture Notes in Computer Science 2006, 4146:49-59.
35. Batagov AO, Yarmishyn AA, Jenjaroenpun P, Tan JZ, Nishida Y, Kurochkin IV:Role of genomic architecture in the expression dynamics of long noncoding RNAs during differentiation of human neuroblastoma cells. BMC Syst Biol 2013, 7:(Suppl 3):S11.
36. Cornero A, Acquaviva M, Fardin P, Versteeg R, Schramm A, Eva A, Bosco MC, Blengio F, Barzaghi S, Varesio L:Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome. BMC Bioinformatics 2012, 13:(Suppl 4):S13.
37. Encinas M, Iglesias M, Llecha N, Comella JX: Extracellular-regulated kinases and phosphatidylinositol 3-kinase are involved in brain-derived neurotrophic factor-mediated survival and neuritogenesis of the neuroblastoma cell line SH-SY5Y. J Neurochem 1999, 73:1409-1421.
38. Mattick JS:The genetic signatures of noncoding RNAs. PLoS Genet 2009, 5:e1000459.
39. St Laurent G1, Shtokalo D, Tackett MR, Yang Z, Eremina T, Wahlestedt C, Urcuqui-Inchima S, Seilheimer B, McCaffrey TA, Kapranov P: Intronic RNAs constitute the major fraction of the non-coding RNA in mammalian cells. BMC Genomics 2012, 13:504.
40. Tahira AC1, Kubrusly MS, Faria MF, Dazzani B, Fonseca RS, Maracaja-Coutinho V, Verjovski-Almeida S, Machado MC, Reis EM: Long noncoding intronic RNAs are differentially expressed in primary and metastatic pancreatic cancer. Mol Cancer 2011, 10:141.
41. Shah N, Sukumar S: The Hox genes and their roles in oncogenesis. Nat Rev Cancer 2010, 10:361-371.
42. Murphy WJ, Pringle TH, Crider TA, Springer MS, Miller W: Using genomic data to unravel the root of the placental mammal phylogeny. Genome Res 2007, 17:413-421.
43. Tavaré S, Marshall CR, Will O, Soligo C, Martin RD: Using the fossil record to estimate the age of the last common ancestor of extant primates. Nature 2002, 416:726-729.
44. Raaum RL, Sterner KN, Noviello CM, Stewart CB, Disotell TR: Catarrhine primate divergence dates estimated from complete mitochondrial genomes: concordance with fossil and nuclear DNA evidence. J Hum Evol 2005, 48:237-257.
45. Miyazaki YJ, Hamada J, Tada M, Furuuchi K, Takahashi Y, Kondo S, Katoh H, Moriuchi T: HOXD3 enhances motility and invasiveness through the TGFbeta- dependent and -independent pathways in A549 cells. Oncogene 2002, 21:798-808.
46. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Widschwendter M, Vierkant RA, Larson MC, Kjaer SK, Birrer MJ, Berchuck A, Schildkraut J, Tomlinson I, Kiemeney LA, Cook LS, Gronwald J, Garcia-Closas M, Gore ME, Campbell I, Whittemore AS, Sutphen R, Phelan C, Anton-Culver H, Pearce CL, Lambrechts D, Rossing MA, Chang-Claude J, Moysich KB, Goodman MT, et al: A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 2010, 42:874-879.
47. Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, Yanagisawa K, Mitsudomi T, Takahashi T: Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol 2006, 24:1679-1688.
48. Champine PJ, Michaelson J, Weimer BC, Welch DR, DeWald DB: Microarray analysis reveals potential mechanisms of BRMS1-mediated metastasis suppression. ClinExp Metastasis 2007, 24:551-565.
49. Lee DC, Kang YK, Kim WH, Jang YJ, Kim DJ, Park IY, Sohn BH, Sohn HA, Lee HG, Lim JS, Kim JW, Song EY, Kim DM, Lee MN, Oh GT, Kim SJ, Park KC, Yoo HS, Choi JY, Yeom YI: Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis. Cancer Res 2008, 68:4210-4220.
50. Sabates-Bellver J, Van der Flier LG, de Palo M, Cattaneo E, Maake C, Rehrauer H, Laczko E, Kurowski MA, Bujnicki JM, Menigatti M, Luz J, Ranalli TV, Gomes V, Pastorelli A, Faggiani R, Anti M, Jiricny J, Clevers H, Marra G: Transcriptome profile of human colorectal adenomas. Mol Cancer Res 2007, 5:1263-1275.
51. Thiele CJ, Li Z, McKee AE: On Trk-the TrkB signal transduction pathway is an increasingly important target in cancer biology. Clin Cancer Res 2009, 15:5962-5967.
52. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, McCubrey JA: Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003, 17:590-603.
53. Opel D, Poremba C, Simon T, Debatin KM, Fulda S: Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res 2007, 67:735-745.
54. Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM: Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 1994, 14:759-767.
55. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM: Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993, 328:847-854.
56. Yamashiro DJ, Liu XG, Lee CP, Nakagawara A, Ikegaki N, McGregor LM, Baylin SB, Brodeur GM: Expression and function of Trk-C in favourable human neuroblastomas. Eur J Cancer 1997, 33:2054-2057.
57. Clauset A, Shalizi CR, Newman MEJ: Power-law distributions in empirical data. SIAM Review 2009, 51:661-703.
58. Janoueix-Lerosey I, Lequin D, Brugières L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, Valteau-Couanet D, Frebourg T, Michon J, Lyonnet S, Amiel J, Delattre O: Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008, 455:967-970.
59. Benjamini Y, Yekutieli D: The control of the false discovery rate in multiple testing under dependency. Ann Statist 2001, 29:1165-1188.
60. Ohtaki M, Otani K, Hiyama K, Kamei N, Satoh K, Hiyama E: A robust method for estimating gene expression states using Affymetrix microarray probe level data. BMC Bioinformatics 2010, 11:183.
61. Tibshirani R, Hastie T, Narasimhan B, Chu G: Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2002, 99:6567-6572.